A chimeric live attenuated vaccine against Japanese encephalitis

References

• Solomon T, Mallewa M. Dengue and other emerging flaviviruses. J. Infect. 42,104–115 (2001).
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology In: Japanese Encephalitis and West Nile Viruws MacKenzie JS, Barrett ADT, Deubel V (Eds), Springer-Verlag, Berlin, 11–48 (2002).
   Google Scholar
• Rao DR, Reuben R, Nagasampagi BA. Development of combined use of neem (azadirachta indica) and water management for the control of culicine mosquitoes in rice fields. Med. Vet. EntymoL 9,29–33 (1995).
   Google Scholar
• World Health Organization. Japanese encephalitis vaccines: WHO position paper. Wkly EpidemioL Rec. 73,337–344 (1998).
   PubMedGoogle Scholar
• •Reviews the then (1995) status of JE vaccines.
   Google Scholar
• Barrett AD. Current status of Flavivirus vaccines. Ann. NY Acad. Sci. 951,262–271 (2001).
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Lee SH et aL A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557–4565 (2001).
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Guirakhoo F, Trent DW, Monath TE Traditional and novel approaches to flavivirus vaccines. Int. J. ParasitoL 33,567–582 (2003).
   PubMed Web of Science ®Google Scholar
• •Describes the current (2003) status of flavivirus (including JE) vaccines both in development and clinical trials.
   Google Scholar
• Plesner AM. Allergic reactions to Japanese encephalitis vaccines. ImmunoL Allergy Clin. North Am. 23,665–697 (2003).
   PubMed Web of Science ®Google Scholar
• Kanesa-thasan N, Smucny JJ, Hoke CH et aL Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19, 483–491 (2000).
   PubMed Web of Science ®Google Scholar
• Chang GJ, Davis BS, Hunt AR, Holmes DA, Kuno G. Flavivirus DNA vaccines: current status and potential. Ann. NY Acad. Sci. 951,272-285 (2001).
   Google Scholar
• Tanabayashi K, Mukai R, Yamada A et al. Immunogenicity of a Japanese encephalitis DNA vaccine candidate in cynomolgus monkeys. Vaccine 21, 2338–2345 (2003).
   PubMed Web of Science ®Google Scholar
• Monath TE Yellow fever vaccine. In: Vaccines, 3rd Edition. Plotkin S, Orenstein W (Eds). WB Saunders, PA, USA, 815–880 (1999).
   Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. ViroL 73, 3095–3101 (1999).
   PubMed Web of Science ®Google Scholar
• •Describes the genetic engineering underlying the ChimerVax platform technology.
   Google Scholar
• Monath TP, Soike K, Levenbook I et al. Recombinant chimaeric live, attenuated vaccine (ChimeriVax cm) incorporating the envelope genes of Japanese encephalitis (5A14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine 17, 1869–1882 (1999).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability and protective efficacy of a recombinant chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology257,363–372 (1999).
   PubMed Web of Science ®Google Scholar
• Monath TP, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. ViroL 74,1742–1751 (2000).
   Google Scholar
• Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax cm: recombinant live attenuated vaccines against flavivirus infections. Vaccine 20,1004–1018 (2002).
   PubMed Web of Science ®Google Scholar
• •• The authors present the first clinical data describing the safety, tolerability and immunogenicity of ChimeriVax-JE.
   Google Scholar
• Monath TP, Guirakhoo F, Nichols R etal. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase II clinical trials for safety and irnmunogenicity, effect of vaccine dose and schedule and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188,1213-1230(2003).
   Google Scholar
• ••Describes results from further clinicaltrials of ChimeriVaxTm-JE demonstrating safety, immunogenicity, dose response, lack of antivector immunity, and efficacy.
   Google Scholar
• Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination — United States, 2001-2002. JAMA 288, 2533–2535 (2002).
   Web of Science ®Google Scholar
• Perelygin AA, Scherbik SV, Zhulin IB et aL Positional cloning of the murine flavivirus resistance gene. Proc. Natl Acad. Sci. USA 99,9322–9327 (2002).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue Type 2 virus is immunogenic and protective in nonhuman primates. J ViroL 74,5477–5485 (2000).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Pugachev KM, Arroyo J et aL Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstruction, dose adjustment and antibody responses against wild type dengue virus isolates. Virology 298, 146–159 (2002).
   PubMed Web of Science ®Google Scholar
• Monath TP, Arroyo J, Miller C, Guirakhoo E West Nile virus vaccine. CUIT: Drug Targets Infect. Disord. 1,37–50 (2001).
   Google Scholar
• Tesh RB, Arroyo J, Travassos Da Rosa AP et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8,1392–1397 (2002).
   Google Scholar